BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[FDA raises issues with Genzyme's leukemia drug study]]>http://www.bloggingstocks.com/2009/08/28/fda-raises-issues-with-genzymes-leukemia-drug-study/http://www.bloggingstocks.com/2009/08/28/fda-raises-issues-with-genzymes-leukemia-drug-study/http://www.bloggingstocks.com/2009/08/28/fda-raises-issues-with-genzymes-leukemia-drug-study/#commentsFiled under: , ,

The U.S. Food and Drug Administration (FDA) has some questions for Genzyme Corp. (NASDAQ: GENZ) regarding trial data for its leukemia drug, Clolar. Because Genzyme didn't follow the FDA's recommendations in conducting its main study of Clolar, the regulatory agency is reluctant to make a decision on the basis of the trial results.

In 2007, FDA staff advised Genzyme to conduct a randomized study in which participants receiving Clolar would be compared against a set of patients not receiving the drug. However, the drug company's primary tests did not include a control group; instead, the treatment was tested only on elderly patients with acute myeloid leukemia (AML).

Continue reading FDA raises issues with Genzyme's leukemia drug study

FDA raises issues with Genzyme's leukemia drug study originally appeared on BloggingStocks on Fri, 28 Aug 2009 13:45:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>analystsClolarFDAfood and drug administrationGENZGenzymeinthenewsoptionsshort interestshort sellerstechnical analysisZacksFri, 28 Aug 2009 13:45:00 EST